Published in Healthcare Mergers, Acquisitions and Ventures Week, December 23rd, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alnylam Pharmaceuticals.
Report 1: Alnylam Pharmaceuticals, Inc., (ALNY) has initiated a phase I human clinical trial of an inhaled formulation of ALN-RSV01 in the U.S. to evaluate its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
The inhaled formulation of ALN-RSV01 used in this phase I study is a nebulized formulation, and advances previous clinical work for ALN-RSV01 administered as an intranasal spray. ALN-RSV01, an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.